Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Blood and Marrow Transplant Group of Georgia | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This trial will evaluate the safety and efficacy of post-transplant Cy and sirolimus following reduced intensity allogeneic SCT. It is hoped that the combination of a reduced intensity preparative regimen with a calcineurin-free GVHD prophylaxis regimen will decrease the risk of acute and chronic GVHD, by both limiting mucosal toxicity and augmenting immune reconstitution, thereby improving the safety of the procedure. The past experience with post-transplant Cy suggests that SCT recipients will attain rapid donor T cell chimerism, which the investigators hope will translate into improved disease control through the well documented graft-versus-malignancy effects of donor T cells.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Reduced Intensity Allogeneic Stem Cell Transplantation | Experimental | All patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Allogeneic Hematopoietic Stem Cell Transplantation | Procedure | Patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of GVHD | To estimate the incidence of graft-versus-host disease (GVHD) when utilizing post-transplant cyclophosphamide (Cy) and sirolimus for GVHD prophylaxis following reduced intensity allogeneic hematopoietic stem cell transplantation (SCT) in patients with high risk hematologic malignancies. | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of Absolute Neutrophil Count (ANC)/Platelet Engraftment | To estimate the incidence of neutrophil and platelet engraftment | Approximately Day 30 |
| Number of Participants With Non-Relapse Mortality |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Scott R Solomon, MD | Blood and Marrow Transplant Group of Georgia | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Northside Hospital | Atlanta | Georgia | 30342 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 9164184 | Background | Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH, Bradley BA, Casper JT, Flomenberg N, Gajewski JL, Gluckman E, Henslee-Downey PJ, Hows JM, Jacobsen N, Kolb HJ, Lowenberg B, Masaoka T, Rowlings PA, Sondel PM, van Bekkum DW, van Rood JJ, Vowels MR, Zhang MJ, Horowitz MM. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol. 1997 May;15(5):1767-77. doi: 10.1200/JCO.1997.15.5.1767. | |
| 19604243 |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Reduced Intensity Allogeneic Stem Cell Transplantation | All patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis. Allogeneic Hematopoietic Stem Cell Transplantation: Patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis. |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Reduced Intensity Allogeneic Stem Cell Transplantation | All patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis. Allogeneic Hematopoietic Stem Cell Transplantation: Patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Incidence of GVHD | To estimate the incidence of graft-versus-host disease (GVHD) when utilizing post-transplant cyclophosphamide (Cy) and sirolimus for GVHD prophylaxis following reduced intensity allogeneic hematopoietic stem cell transplantation (SCT) in patients with high risk hematologic malignancies. | Posted | Number | participants | 1 year |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Reduced Intensity Allogeneic Stem Cell Transplantation | All patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis. Allogeneic Hematopoietic Stem Cell Transplantation: Patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| pneumonia | Respiratory, thoracic and mediastinal disorders |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nausea | Gastrointestinal disorders | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Scott R. Solomon, MD | Blood and Marrow Transplant Group of Georgia | 404-255-1930 | ssolomon@bmtga.com |
Not provided
| ID | Term |
|---|---|
| D019337 | Hematologic Neoplasms |
| D015464 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
| D015470 | Leukemia, Myeloid, Acute |
| D009190 | Myelodysplastic Syndromes |
| D055728 | Primary Myelofibrosis |
| D054198 | Precursor Cell Lymphoblastic Leukemia-Lymphoma |
| D015451 | Leukemia, Lymphocytic, Chronic, B-Cell |
| D015463 | Leukemia, Prolymphocytic |
| D020522 | Lymphoma, Mantle-Cell |
| D006689 | Hodgkin Disease |
| D054219 | Neoplasms, Plasma Cell |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 1 year |
| Number of Patients With Disease Free Survival at 2 Years | 2 years |
| Number of Patients to Achieve Full Donor Chimerism | Characterize rate of achievement of full donor chimerism | 1 year |
| Number of Patients With Overall Survival at 2 Years. | 2 years |
| Background |
| de Witte T, Brand R, van Biezen A, Mufti G, Ruutu T, Finke J, von dem Borne P, Vitek A, Delforge M, Alessandrino P, Harlahakis N, Russell N, Martino R, Verdonck L, Kroger N, Niederwieser D; European Blood and Marrow Transplantation Group (EBMT), Chronic Leukemia Working Party (CLWP)-MDS subcommittee. Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival. Br J Haematol. 2009 Sep;146(6):627-36. doi: 10.1111/j.1365-2141.2009.07809.x. Epub 2009 Jul 14. |
| 19151786 | Background | Basara N, Schulze A, Wedding U, Mohren M, Gerhardt A, Junghanss C, Peter N, Dolken G, Becker C, Heyn S, Kliem C, Lange T, Krahl R, Ponisch W, Fricke HJ, Sayer HG, Al-Ali H, Kamprad F, Niederwieser D; East German Study Group Hematology and Oncology (OSHO). Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission. Leukemia. 2009 Apr;23(4):635-40. doi: 10.1038/leu.2008.352. Epub 2009 Jan 8. |
| 18022580 | Background | Mielcarek M, Storer BE, Sandmaier BM, Sorror ML, Maloney DG, Petersdorf E, Martin PJ, Storb R. Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. Biol Blood Marrow Transplant. 2007 Dec;13(12):1499-507. doi: 10.1016/j.bbmt.2007.09.004. |
| 11986199 | Background | Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002 May 15;99(10):3493-9. doi: 10.1182/blood.v99.10.3493. |
| 12925844 | Background | Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003 Sep;9(9):1144-50. doi: 10.1038/nm915. Epub 2003 Aug 17. |
| 14660744 | Background | Trenado A, Charlotte F, Fisson S, Yagello M, Klatzmann D, Salomon BL, Cohen JL. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest. 2003 Dec;112(11):1688-96. doi: 10.1172/JCI17702. |
| 18550852 | Background | Zhao D, Zhang C, Yi T, Lin CL, Todorov I, Kandeel F, Forman S, Zeng D. In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease. Blood. 2008 Sep 1;112(5):2129-38. doi: 10.1182/blood-2008-02-140277. Epub 2008 Jun 12. |
| 15972448 | Background | Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S, Bellucci R, Alyea EP, Antin JH, Soiffer RJ, Ritz J. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005 Oct 15;106(8):2903-11. doi: 10.1182/blood-2005-03-1257. Epub 2005 Jun 21. |
| 16278306 | Background | Rieger K, Loddenkemper C, Maul J, Fietz T, Wolff D, Terpe H, Steiner B, Berg E, Miehlke S, Bornhauser M, Schneider T, Zeitz M, Stein H, Thiel E, Duchmann R, Uharek L. Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood. 2006 Feb 15;107(4):1717-23. doi: 10.1182/blood-2005-06-2529. Epub 2005 Nov 8. |
| 16627754 | Background | Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J, Keyvanfar K, Montero A, Hensel N, Kurlander R, Barrett AJ. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood. 2006 Aug 15;108(4):1291-7. doi: 10.1182/blood-2006-02-003996. Epub 2006 Apr 20. |
| 17351648 | Background | Coenen JJ, Koenen HJ, van Rijssen E, Kasran A, Boon L, Hilbrands LB, Joosten I. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells. Bone Marrow Transplant. 2007 May;39(9):537-45. doi: 10.1038/sj.bmt.1705628. Epub 2007 Mar 12. |
| 16522809 | Background | Zeiser R, Nguyen VH, Beilhack A, Buess M, Schulz S, Baker J, Contag CH, Negrin RS. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood. 2006 Jul 1;108(1):390-9. doi: 10.1182/blood-2006-01-0329. Epub 2006 Mar 7. |
| 8019473 | Background | Lehnert S, Rybka WB. Amplification of the graft-versus-host reaction by cyclophosphamide: dependence on timing of drug administration. Bone Marrow Transplant. 1994 Apr;13(4):473-7. |
| 9032788 | Background | Mayumi H. [Cyclophosphamide-induced immunological tolerance: an overview]. Nihon Geka Gakkai Zasshi. 1996 Dec;97(12):1097-108. Japanese. |
| 3307052 | Background | Mayumi H, Himeno K, Tanaka K, Tokuda N, Fan JL, Nomoto K. Drug-induced tolerance to allografts in mice. XII. The relationships between tolerance, chimerism, and graft-versus-host disease. Transplantation. 1987 Aug;44(2):286-90. doi: 10.1097/00007890-198708000-00021. |
| 11719388 | Background | Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001 Dec 1;98(12):3456-64. doi: 10.1182/blood.v98.12.3456. |
| 11939602 | Background | Luznik L, Engstrom LW, Iannone R, Fuchs EJ. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant. 2002;8(3):131-8. doi: 10.1053/bbmt.2002.v8.pm11939602. |
| 12171484 | Background | O'Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M, Rhubart P, Cowan K, Piantados S, Fuchs EJ. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8(7):377-86. doi: 10.1053/bbmt.2002.v8.pm12171484. |
| 20124511 | Background | Luznik L, Bolanos-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R, Huff CA, Borrello I, Matsui W, Powell JD, Kasamon Y, Goodman SN, Hess A, Levitsky HI, Ambinder RF, Jones RJ, Fuchs EJ. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010 Apr 22;115(16):3224-30. doi: 10.1182/blood-2009-11-251595. Epub 2010 Feb 2. |
| 15273705 | Background | Uberti JP, Ayash L, Braun T, Reynolds C, Silver S, Ratanatharathorn V. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes. Bone Marrow Transplant. 2004 Sep;34(5):425-31. doi: 10.1038/sj.bmt.1704594. |
| years |
|
| Age, Categorical | Count of Participants | Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
|
|
| Secondary | Incidence of Absolute Neutrophil Count (ANC)/Platelet Engraftment | To estimate the incidence of neutrophil and platelet engraftment | Posted | Number | participants | Approximately Day 30 |
|
|
|
| Secondary | Number of Participants With Non-Relapse Mortality | Posted | Number | participants | 1 year |
|
|
|
| Secondary | Number of Patients With Disease Free Survival at 2 Years | Posted | Number | participants | 2 years |
|
|
|
| Secondary | Number of Patients to Achieve Full Donor Chimerism | Characterize rate of achievement of full donor chimerism | Posted | Number | participants | 1 year |
|
|
|
| Secondary | Number of Patients With Overall Survival at 2 Years. | Posted | Number | participants | 2 years |
|
|
|
| 10 |
| 26 |
| 26 |
| 26 |
| Acute Cholecystitis | Gastrointestinal disorders |
|
| GI bleeding | Gastrointestinal disorders |
|
| pulmonary embolism | Respiratory, thoracic and mediastinal disorders |
|
| cellulitis | Vascular disorders |
|
| VOD | Hepatobiliary disorders |
|
| Severe Hyperglycemia | Investigations |
|
| "cold sweats" | General disorders |
|
| "cold" feeling | General disorders |
|
| abdominal bloating | Gastrointestinal disorders |
|
| abdominal cramps | Gastrointestinal disorders |
|
| abdominal discomfort/pain | Gastrointestinal disorders |
|
| abdominal distention | Gastrointestinal disorders |
|
| abdominal tenderness | Gastrointestinal disorders |
|
| agitation | Psychiatric disorders |
|
| increased alkaline phosphatase | Hepatobiliary disorders |
|
| alopecia | General disorders |
|
| increased alanine aminotransferase | Hepatobiliary disorders |
|
| neutropenia | Blood and lymphatic system disorders |
|
| anemia | Blood and lymphatic system disorders |
|
| anorexia/decreased oral intake | Gastrointestinal disorders |
|
| anxiety | Psychiatric disorders |
|
| arm pain | Musculoskeletal and connective tissue disorders |
|
| ascites | Gastrointestinal disorders |
|
| increased aspartate aminotransferase | Hepatobiliary disorders |
|
| ataxia | Musculoskeletal and connective tissue disorders |
|
| back pain | Musculoskeletal and connective tissue disorders |
|
| bacteremia | Infections and infestations |
|
| bilateral knee pain | Musculoskeletal and connective tissue disorders |
|
| BKV cystitis | Infections and infestations |
|
| bladder cramping | Renal and urinary disorders |
|
| bladder pain | Renal and urinary disorders |
|
| bladder spasms | Renal and urinary disorders |
|
| bloody stool | Gastrointestinal disorders |
|
| blurry vision | Eye disorders |
|
| benign prostatic hyperplasia | Renal and urinary disorders |
|
| bradycardia | Cardiac disorders |
|
| bruising | Skin and subcutaneous tissue disorders |
|
| clostridium difficile colitis | Gastrointestinal disorders |
|
| cellulitis | Infections and infestations |
|
| chest pressure | Cardiac disorders |
|
| chills/rigors | General disorders |
|
| CMV reactivation | Infections and infestations |
|
| confusion | Psychiatric disorders |
|
| constipation | Gastrointestinal disorders |
|
| dry cough | Respiratory, thoracic and mediastinal disorders |
|
| coarse breath sounds | Respiratory, thoracic and mediastinal disorders |
|
| increased creatinine | Renal and urinary disorders |
|
| central venous catheter pain | General disorders |
|
| central venous catheter site drainage | General disorders |
|
| central venous catheter site erythema | General disorders |
|
| deconditioning | General disorders |
|
| decreased appetite | Metabolism and nutrition disorders |
|
| decreased bowel movement frequency | Gastrointestinal disorders |
|
| decreased breath sounds | Respiratory, thoracic and mediastinal disorders |
|
| decreased fluid intake | Metabolism and nutrition disorders |
|
| depression | Psychiatric disorders |
|
| diaphoretic skin | Skin and subcutaneous tissue disorders |
|
| diarrhea | Gastrointestinal disorders |
|
| dysphagia | Gastrointestinal disorders |
|
| dizziness | Nervous system disorders |
|
| drowsiness | Nervous system disorders |
|
| dry eyes | Eye disorders |
|
| dry lips | Gastrointestinal disorders |
|
| dry mouth | Gastrointestinal disorders |
|
| dry skin | Skin and subcutaneous tissue disorders |
|
| deep venous thrombosis | Vascular disorders |
|
| dysuria | Renal and urinary disorders |
|
| ear fullness/pressure | Ear and labyrinth disorders |
|
| electrolyte wasting syndrome | Metabolism and nutrition disorders |
|
| enlarged lymph nodes | Blood and lymphatic system disorders |
|
| epigastric pain | Gastrointestinal disorders |
|
| epistaxis | Respiratory, thoracic and mediastinal disorders |
|
| esophagitis | Gastrointestinal disorders |
|
| excoriation | Skin and subcutaneous tissue disorders |
|
| facial edema | General disorders |
|
| fatigue | General disorders |
|
| fever | General disorders |
|
| flat affect | Psychiatric disorders |
|
| fluid overload | Vascular disorders |
|
| facial flushing | Vascular disorders |
|
| folliculitis | Skin and subcutaneous tissue disorders |
|
| gas/flatulence | Gastrointestinal disorders |
|
| generalized achiness | Musculoskeletal and connective tissue disorders |
|
| generalized skin erythema | Skin and subcutaneous tissue disorders |
|
| GERD | Gastrointestinal disorders |
|
| skin GVHD | Immune system disorders |
|
| gut GVHD | Immune system disorders |
|
| hallucinations | Psychiatric disorders |
|
| headache | Nervous system disorders |
|
| hematoma | Vascular disorders |
|
| hematuria | Renal and urinary disorders |
|
| hemoptysis | Respiratory, thoracic and mediastinal disorders |
|
| perirectal bleeding/hemorrhage | Gastrointestinal disorders |
|
| hemorrhodial edema | Gastrointestinal disorders |
|
| hemorrhodial pain | Gastrointestinal disorders |
|
| hemorrhoids | Gastrointestinal disorders |
|
| hernia | Musculoskeletal and connective tissue disorders |
|
| hives | Skin and subcutaneous tissue disorders |
|
| hyperactive bowel sounds | Gastrointestinal disorders |
|
| hyperbilirubinemia | Hepatobiliary disorders |
|
| hypercalcemia | Metabolism and nutrition disorders |
|
| hyperglycemia | Metabolism and nutrition disorders |
|
| hyperkalemia | Metabolism and nutrition disorders |
|
| hypernatremia | Metabolism and nutrition disorders |
|
| hyperpigmentation | Skin and subcutaneous tissue disorders |
|
| hypertension | Cardiac disorders |
|
| hypoalbuminemia | Metabolism and nutrition disorders |
|
| hypocalcemia | Metabolism and nutrition disorders |
|
| hypoglycemia | Metabolism and nutrition disorders |
|
| hypokalemia | Metabolism and nutrition disorders |
|
| hypomagnesemia | Metabolism and nutrition disorders |
|
| hyponatremia | Metabolism and nutrition disorders |
|
| hypotension | Cardiac disorders |
|
| hypoxemic respiratory failure | Respiratory, thoracic and mediastinal disorders |
|
| stool incontinence | Gastrointestinal disorders |
|
| increased respiration rate | Respiratory, thoracic and mediastinal disorders |
|
| insomnia | Psychiatric disorders |
|
| joint aches | Musculoskeletal and connective tissue disorders |
|
| lower-extremity edema | General disorders |
|
| leg pain | Musculoskeletal and connective tissue disorders |
|
| lethargy | Nervous system disorders |
|
| limited mobility | Musculoskeletal and connective tissue disorders |
|
| lip edema | General disorders |
|
| loss of coordination/balance | Nervous system disorders |
|
| lung crackles | Respiratory, thoracic and mediastinal disorders |
|
| lymphadenopathy | Blood and lymphatic system disorders |
|
| malnutrition | Gastrointestinal disorders |
|
| metabolic acidosis | Metabolism and nutrition disorders |
|
| mouth sores | Gastrointestinal disorders |
|
| mouth tenderness | Gastrointestinal disorders |
|
| MRSE bacteremia | Infections and infestations |
|
| mucositis | Gastrointestinal disorders |
|
| muscle weakness | Musculoskeletal and connective tissue disorders |
|
| nasal congestion | Respiratory, thoracic and mediastinal disorders |
|
| nasal drainage | Respiratory, thoracic and mediastinal disorders |
|
| neuropathy | Nervous system disorders |
|
| febrile neutropenia | Blood and lymphatic system disorders |
|
| nocturia | Renal and urinary disorders |
|
| oral erythema | Skin and subcutaneous tissue disorders |
|
| oral thrush | Vascular disorders |
|
| orthostatic hypotension | Cardiac disorders |
|
| pain during defication | Gastrointestinal disorders |
|
| pain with breathing | Respiratory, thoracic and mediastinal disorders |
|
| hip pain | Musculoskeletal and connective tissue disorders |
|
| foot pain | Musculoskeletal and connective tissue disorders |
|
| lower-extremity pain | Musculoskeletal and connective tissue disorders |
|
| neck pain | Musculoskeletal and connective tissue disorders |
|
| pelvic pain | Musculoskeletal and connective tissue disorders |
|
| shoulder pain | Musculoskeletal and connective tissue disorders |
|
| throat pain | Gastrointestinal disorders |
|
| pale skin | Skin and subcutaneous tissue disorders |
|
| parainfluenza | Respiratory, thoracic and mediastinal disorders |
|
| penile lesions | Skin and subcutaneous tissue disorders |
|
| perihepatic ascites | Hepatobiliary disorders |
|
| periorbital edema | Eye disorders |
|
| periorbital redness | Eye disorders |
|
| peripheral edema | General disorders |
|
| perirectal irritation | Gastrointestinal disorders |
|
| perirectal pain | Gastrointestinal disorders |
|
| petechiae | Blood and lymphatic system disorders |
|
| pleural effusion | Respiratory, thoracic and mediastinal disorders |
|
| pleuritic chest pain | Cardiac disorders |
|
| pneumonia | Respiratory, thoracic and mediastinal disorders |
|
| post-nasal drip | Respiratory, thoracic and mediastinal disorders |
|
| pruritus | Skin and subcutaneous tissue disorders |
|
| pulmonary infiltrates | Respiratory, thoracic and mediastinal disorders |
|
| pulmonary nodules | Respiratory, thoracic and mediastinal disorders |
|
| pulmonary opacites | Respiratory, thoracic and mediastinal disorders |
|
| rash | Skin and subcutaneous tissue disorders |
|
| respiratory distress | Respiratory, thoracic and mediastinal disorders |
|
| respiratory insufficiency | Respiratory, thoracic and mediastinal disorders |
|
| restless leg syndrome | Nervous system disorders |
|
| rhinorrhea | Respiratory, thoracic and mediastinal disorders |
|
| rhinovirus/URI | Respiratory, thoracic and mediastinal disorders |
|
| rhonchi | Respiratory, thoracic and mediastinal disorders |
|
| ribcage tenderness | Musculoskeletal and connective tissue disorders |
|
| seasonal allergies | General disorders |
|
| sedation | Nervous system disorders |
|
| sinus congestion | Respiratory, thoracic and mediastinal disorders |
|
| sinus drainage | Respiratory, thoracic and mediastinal disorders |
|
| sinus pressure | Respiratory, thoracic and mediastinal disorders |
|
| chronic sinusitis | Respiratory, thoracic and mediastinal disorders |
|
| skin abrasion | Skin and subcutaneous tissue disorders |
|
| skin color changes | Skin and subcutaneous tissue disorders |
|
| skin erythema | Skin and subcutaneous tissue disorders |
|
| skin lesions | Skin and subcutaneous tissue disorders |
|
| skin sensitivity | Skin and subcutaneous tissue disorders |
|
| skin tear | Skin and subcutaneous tissue disorders |
|
| skin tenderness | Skin and subcutaneous tissue disorders |
|
| sneezing | Respiratory, thoracic and mediastinal disorders |
|
| shortness of breath | Respiratory, thoracic and mediastinal disorders |
|
| splenomegaly | General disorders |
|
| staphylococcus epidermis bacteremia | Infections and infestations |
|
| steroid-induced diabetes | Metabolism and nutrition disorders |
|
| stomatitis | Gastrointestinal disorders |
|
| suprapubic tenderness | Musculoskeletal and connective tissue disorders |
|
| sweats | Nervous system disorders |
|
| tachycardia | Cardiac disorders |
|
| taste changes | General disorders |
|
| thrombocytopenia | Blood and lymphatic system disorders |
|
| tremors | Nervous system disorders |
|
| unsteady gait | Nervous system disorders |
|
| urinary frequency | Renal and urinary disorders |
|
| urinary hesitancy | Renal and urinary disorders |
|
| urinary incontinence | Renal and urinary disorders |
|
| urinary retention | Renal and urinary disorders |
|
| urinary urgency | Renal and urinary disorders |
|
| urinary tract infection | Renal and urinary disorders |
|
| visual changes | Nervous system disorders |
|
| veno-occlusive disease | Hepatobiliary disorders |
|
| volume depletion | General disorders |
|
| vomiting | Gastrointestinal disorders |
|
| VRE positive | Infections and infestations |
|
| leukopenia | Blood and lymphatic system disorders |
|
| generalized weakness | General disorders |
|
| weight gain | Investigations |
|
| weight loss | Investigations |
|
| wheezing | Respiratory, thoracic and mediastinal disorders |
|
Not provided
Not provided
Not provided
| D007951 |
| Leukemia, Myeloid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009196 | Myeloproliferative Disorders |
| D001855 | Bone Marrow Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D007945 | Leukemia, Lymphoid |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D015448 | Leukemia, B-Cell |
| D008228 | Lymphoma, Non-Hodgkin |
| D008223 | Lymphoma |